CClaimWatch
Plaintiff counsel in 3 cases

Joseph Alexander Hood , II

Pomerantz LLP

Address of record
600 Third Avenue, 20th Floor, New York, NY 10016, 212-661-1100
Email
ahood@pomlaw.com
Phone
(212) 661-1100
Fax
Fax 212-661-8665

Contact details as filed with the court in the cases below.

4
Cases tracked
0 active · 4 settled
$186.8M
Plaintiff-side recovery
Disclosed settlement funds
—
Defense-side exposure
Resolved in settlements
4
Cases with values
of 4 tracked

Case history

Publicly tracked matters where this attorney is listed as counsel.

Plaintiff counselSettled — claims closed

ImmunityBio Inc. Securities Litigation Settlement

Lead Plaintiff alleges that ImmunityBio, Inc. and its executives made false or misleading statements regarding the company's securities during the class period. The defendants have agreed to settle the litigation for $10,500,000 in cash without admitting wrongdoing.

Settlement fund
$10.5M
Claim deadline
July 7, 2025
Represents
Zachary Salzman
Plaintiff counselSettled — claims closed

Silvergate Capital Corporation Securities Litigation Settlement

Investors alleged that Silvergate Capital Corporation violated federal securities laws by making false and misleading statements about Silvergate Bank's vetting, due diligence, and monitoring of customers. Silvergate Capital has settled the claims for $37.5 million in cash without admitting wrongdoing.

Settlement fund
$37.5M
Claim deadline
October 21, 2025
Represents
Jacob Guz
Plaintiff counselSettled — claims closed

Turquoise Hill Resources Ltd. Securities Litigation Settlement

Rio Tinto plc, Rio Tinto Limited, and two executives made material misrepresentations and omissions about Turquoise Hill Resources' business, including misstatements about the development of the Oyu Tolgoi mine in Mongolia and related delays and cost overruns. Rio Tinto agreed to settle for $138.75 million without admitting wrongdoing.

Settlement fund
$138.8M
Claim deadline
September 24, 2025
Represents
Nicholas Lion
CounselSettled — claims closed

Taro Pharmaceutical Industries Ltd. Securities Litigation

Taro Pharmaceutical Industries Ltd. and its executives allegedly made misleading statements about the company's business and prospects, causing the stock price to decline. Investors who purchased Taro common stock during the class period are entitled to recover damages from the settlement. The defendants deny all wrongdoing but have agreed to settle the litigation.

Settlement fund
$36M
Claim deadline
August 16, 2024
Represents
Yuval Lapiner, Liew Han Liang

“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.